172 related articles for article (PubMed ID: 9484875)
1. Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis.
Langan CE; Cranfield R; Breisch S; Pettit R
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():63-72. PubMed ID: 9484875
[TBL] [Abstract][Full Text] [Related]
2. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia.
O'Doherty B; Dutchman DA; Pettit R; Maroli A
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():73-81. PubMed ID: 9484876
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis.
Langan CE; Zuck P; Vogel F; McIvor A; Peirzchala W; Smakal M; Staley H; Marr C
J Antimicrob Chemother; 1999 Oct; 44(4):515-23. PubMed ID: 10588313
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of short-course therapy (5 days) with grepafloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis.
DeAbate CA; Bettis R; Munk ZM; Fleming H; Munn NJ; Riffer E; Bagby B; Giguere G; Collins JJ
Clin Ther; 1999 Jan; 21(1):172-88. PubMed ID: 10090434
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily.
Chodosh S; Lakshminarayan S; Swarz H; Breisch S
Antimicrob Agents Chemother; 1998 Jan; 42(1):114-20. PubMed ID: 9449270
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables.
Tran JQ; Ballow CH; Forrest A; Hyatt JM; Sands MF; Peloquin CA; Schentag JJ
J Antimicrob Chemother; 2000 Mar; 45():9-17. PubMed ID: 10719007
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis.
Forrest A; Chodosh S; Amantea MA; Collins DA; Schentag JJ
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():45-57. PubMed ID: 9484873
[TBL] [Abstract][Full Text] [Related]
8. Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: a multicenter, double-blind, randomized, comparative study. Sparfloxacin Multicenter ABECB Study Group.
DeAbate CA; Henry D; Bensch G; Jubran A; Chodosh S; Harper L; Tipping D; Talbot GH
Chest; 1998 Jul; 114(1):120-30. PubMed ID: 9674458
[TBL] [Abstract][Full Text] [Related]
9. Randomized, double-blind, double-dummy study comparing the efficacy and safety of amoxycillin 1 g bd with amoxycillin 500 mg tds in the treatment of acute exacerbations of chronic bronchitis.
Georgopoulos A; Borek M; Ridl W;
J Antimicrob Chemother; 2001 Jan; 47(1):67-76. PubMed ID: 11152433
[TBL] [Abstract][Full Text] [Related]
10. Double-blind, comparative study of rufloxacin once daily versus amoxicillin three times a day in treatment of outpatients with exacerbations of chronic bronchitis.
Klietmann W; Cesana M; Rondel RK; Focht J
Antimicrob Agents Chemother; 1993 Nov; 37(11):2298-306. PubMed ID: 8285609
[TBL] [Abstract][Full Text] [Related]
11. Treatment of acute exacerbations of chronic bronchitis: comparison of trovafloxacin and amoxicillin in a multicentre, double-blind, double-dummy study. Trovafloxacin Bronchitis Study Group.
O'Doherty B; Daniel R
Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):441-6. PubMed ID: 9758290
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind study of prulifloxacin versus ciprofloxacin in patients with acute exacerbations of chronic bronchitis.
Grassi C; Salvatori E; Rosignoli MT; Dionisio P;
Respiration; 2002; 69(3):217-22. PubMed ID: 12097764
[TBL] [Abstract][Full Text] [Related]
13. Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a double-blind, randomised, parallel, multicentre study.
Allegra L; Konietzko N; Leophonte P; Hosie J; Pauwels R; Guyen JN; Petitpretz P
J Antimicrob Chemother; 1996 May; 37 Suppl A():93-104. PubMed ID: 8737129
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of grepafloxacin 600 mg daily for 10 days in patients with community-acquired pneumonia.
Topkis S; Swarz H; Breisch SA; Maroli AN
Clin Ther; 1997; 19(5):975-88. PubMed ID: 9385485
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of lomefloxacin versus cefaclor in the treatment of acute exacerbations of chronic bronchitis.
Gotfried MH; Ellison WT
Am J Med; 1992 Apr; 92(4A):108S-113S. PubMed ID: 1316059
[TBL] [Abstract][Full Text] [Related]
16. Grepafloxacin: an overview of antibacterial activity, pharmacokinetics, clinical efficacy and safety.
Geddes AM
Expert Opin Investig Drugs; 1999 Apr; 8(4):487-505. PubMed ID: 15992094
[TBL] [Abstract][Full Text] [Related]
17. The activity of grepafloxacin against respiratory pathogens in the UK.
Wise R; Andrews JM
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():27-30. PubMed ID: 9484870
[TBL] [Abstract][Full Text] [Related]
18. A double-blind study of two dosage regimens of lomefloxacin in bacteriologically proven exacerbations of chronic bronchitis of gram-negative etiology.
Kemper P; Köhler D
Am J Med; 1992 Apr; 92(4A):98S-102S. PubMed ID: 1316079
[TBL] [Abstract][Full Text] [Related]
19. Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. The 070 Clinical Study group.
File T; Schlemmer B; Garau J; Lode H; Lynch S; Young C
J Chemother; 2000 Aug; 12(4):314-25. PubMed ID: 10949981
[TBL] [Abstract][Full Text] [Related]
20. Treating acute bacterial exacerbations of chronic bronchitis in patients unresponsive to previous therapy: sparfloxacin versus clarithromycin.
Lipsky BA; Unowsky J; Zhang H; Townsend L; Talbot GH
Clin Ther; 1999 Jun; 21(6):954-65. PubMed ID: 10440620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
